, Bone Cancer, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00667499
Advances in the management of osteosarcoma, 2016. ,
, , vol.4, pp.25-43
Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: A single center experience of 102 patients, Clin. Transl. Oncol, vol.18, pp.937-944, 2016. ,
A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era, Sarcoma, vol.704872, 2012. ,
Drugs in early clinical development for the treatment of osteosarcoma, Expert Opin. Investig. Drugs, vol.25, pp.1265-1280, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466096
Translational biology of osteosarcoma, Nat. Rev. Cancer, vol.14, pp.722-735, 2014. ,
The bone remodelling cycle, Ann. Clin. Biochem, 2018. ,
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front. Immunol, vol.5, 2014. ,
Matrix-embedded cells control osteoclast formation, Nat. Med, vol.17, pp.1235-1241, 2011. ,
RANKL and RANK: From Mammalian Physiology to Cancer Treatment, Trends Cell Biol, vol.28, pp.213-223, 2018. ,
The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling, Cytokine Growth Factor Rev, vol.15, pp.457-475, 2004. ,
Expression pattern of receptor activator of NF?B (RANK) in a series of primary solid tumors and related bone metastases, J. Cell. Physiol, vol.226, pp.780-784, 2011. ,
DU145 human prostate cancer cells express functional receptor activator of NF?B: New insights in the prostate cancer bone metastasis process, vol.40, pp.981-990, 2007. ,
The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: Potential targets for anticancer therapy, vol.10, pp.3801-3810, 2017. ,
RANKL/RANK: From bone loss to the prevention of breast cancer, Open Biol, vol.6, 2016. ,
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Res, vol.67, pp.7308-7318, 2007. ,
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, Am. J. Pathol, vol.163, pp.2021-2031, 2003. ,
The vicious cycle of bone metastases, J. Musculoskelet. Neuronal Interact, vol.2, pp.570-572, 2002. ,
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells, J. Cell Sci, vol.125, pp.943-955, 2012. ,
Role of RANKL (TNFSF11)-dependent osteopetrosis in the dental phenotype of Msx2 null mutant mice, PLoS ONE, vol.8, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01538404
RANKL blockade prevents and treats aggressive osteosarcomas, Sci. Transl. Med, vol.7, 2015. ,
RANK-RANKL signalling in cancer, Biosci. Rep, vol.36, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01644732
Impact of RANK signalling on survival and chemotherapy response in osteosarcoma, Pathology, vol.46, pp.411-415, 2014. ,
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, J. Pathol, vol.211, pp.555-562, 2007. ,
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, Int. J. Oncol, vol.28, pp.261-269, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667510
Receptor activator of nuclear factor ?B expression is a prognostic factor in human osteosarcoma, Oncol. Lett, vol.10, pp.1813-1815, 2015. ,
c-FLIP, a master anti-apoptotic regulator, Exp. Oncol, vol.34, pp.176-184, 2012. ,
, , vol.5, pp.1024-1039, 2015.
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis, Nature, vol.468, pp.103-107, 2010. ,
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nat. Commun, vol.5, 2014. ,
Physiology and pathophysiology of the RANKL/RANK system, Biol. Chem, vol.391, pp.1365-1370, 2010. ,
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit, Proc. Natl. Acad. Sci, vol.108, pp.5342-5347, 2011. ,
RANKL/RANK-from bone physiology to breast cancer, Cytokine Growth Factor Rev, vol.25, pp.205-214, 2014. ,
DOI : 10.1016/j.cytogfr.2014.01.002
Giant cell tumour of bone, Curr. Opin. Oncol, vol.21, pp.338-344, 2009. ,
CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression, Oncotarget, vol.8, pp.87848-87859, 2017. ,
DOI : 10.18632/oncotarget.21254
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=21254&path%5B%5D=67633
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model, Breast Cancer Res. Treat, vol.135, pp.771-780, 2012. ,
RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease, World J. Urol, vol.36, pp.187-192, 2018. ,
DOI : 10.1007/s00345-017-2145-y
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro, PLoS ONE, vol.8, 2013. ,
Diagnosis and management of infectious complications in critically ill patients with cancer, Crit. Care Clin, vol.26, pp.59-91, 2010. ,
Increased osteoclast activity is associated with aggressiveness of osteosarcoma, Int. J. Oncol, vol.33, pp.1231-1238, 2008. ,
LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption, Nat. Med, vol.22, pp.539-546, 2016. ,
DOI : 10.1038/nm.4076
Stat3 Upregulates Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4 Expression in Osteosarcoma Cells, BioMed Res. Int, 2013. ,
DOI : 10.1155/2013/310691
URL : http://downloads.hindawi.com/journals/bmri/2013/310691.pdf
Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition, J. Biol. Chem, vol.292, pp.15525-15537, 2017. ,
DOI : 10.1074/jbc.m116.771931
URL : http://www.jbc.org/content/292/37/15525.full.pdf
Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma, Vivo Athens Greece, vol.16, pp.223-228, 2002. ,
A third-generation lentivirus vector with a conditional packaging system, J. Virol, vol.72, pp.8463-8471, 1998. ,
Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid, vol.73, pp.51-59, 2015. ,
Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody, Biochem. Biophys. Res. Commun, vol.347, pp.124-132, 2006. ,
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466103